title: Leukotrienes do not regulate nitric oxide production in RAW 264.7 macrophages.
abstract: RAW 264.7 macrophages respond to lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma) by producing large amounts of nitric oxide (NO) and prostaglandin E2 (PGE2), with maximal production 18-24 h after treatment. Following stimulation with the calcium inophore A23187, cultures of RAW cells also produce modest amounts of leukotrienes. However, the capacity of these cells to produce leukotrienes is transient, beginning 2 h after vehicle or LPS/IFN-gamma treatment, peaking by 4-6 h and absent by 8 h. A-79175, (R(+) N-[3-[5-(4-Fluorophenoxy)-2-furanyl]-1-methyl-2-propynyl]-N-hydroxyurea) a specific inhibitor of 5-lipoxygenase (5-LO), abolished leukotriene production by RAW cells in a dose-dependent, non-cytotoxic fashion while having no effect on PGE2 or NO production. By contrast, nordihydroguaiaretic acid (NDGA) inhibited production of leukotrienes, PGE2 and NO only at doses that were cytotoxic to the RAW cells. Exogenous leukotriene B4 (LTB4) had no effect on either NO or PGE2 production. An inhibitor of NO production, L-N-5-(1-iminoethyl) ornithine HCl (NIO) also did not affect leukotriene or PGE2 production, while dexamethasone blocked PGE2 and NO production, but did not affect leukotriene production in these cells. Taken collectively, these results indicate that there is no interaction between the pathways for leukotriene and nitric oxide production in RAW 264.7 macrophages.
authors.affiliation: Abbott Laboratories, Immunosciences Research, Abbott Park, IL 60064-3500, USA.
authors.forename: K I
authors.initials: KI
authors.lastname: Hulkower
authors.forename: J S
authors.initials: JS
authors.lastname: Pollock
authors.forename: R E
authors.initials: RE
authors.lastname: Walsh
authors.forename: R
authors.initials: R
authors.lastname: Huang
authors.forename: E R
authors.initials: ER
authors.lastname: Otis
authors.forename: C D
authors.initials: CD
authors.lastname: Brooks
authors.forename: R L
authors.initials: RL
authors.lastname: Bell
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D003907:Dexamethasone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005786:Gene Expression Regulation; D006918:Hydroxyurea / Q000031:analogs & derivatives / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology; D007975:Leukotriene B4 / Q000494:pharmacology; D015289:Leukotrienes / Q000378:metabolism*; D008070:Lipopolysaccharides / Q000494:pharmacology; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D008264:Macrophages / Q000378:metabolism*; D009637:Masoprocol / Q000494:pharmacology; D051379:Mice; D009569:Nitric Oxide / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000096:biosynthesis; D009573:Nitrites / Q000378:metabolism; D015290:Second Messenger Systems; D018675:Toxicity Tests
chemical_list: D015289:Leukotrienes; D008070:Lipopolysaccharides; D016859:Lipoxygenase Inhibitors; D009573:Nitrites; C082739:A 78773; D007975:Leukotriene B4; D009569:Nitric Oxide; D009637:Masoprocol; D003907:Dexamethasone; D007371:Interferon-gamma; D019001:Nitric Oxide Synthase; D006918:Hydroxyurea